Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · Real-Time Price · USD

15.26

+0.89 (6.19%)

Feb 26, 2026, 4:00 PM EST - Market closed

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Researching and Developing Therapeutics for Neurodegenerative Disorders	87.37M	380.79M	22.23M	285.00K	650.00K
Researching and Developing Therapeutics for Neurodegenerative Disorders Growth	-77.06%	1612.94%	7700.00%	-56.15%	-54.42%
Total	87.37M	380.79M	22.23M	285.00K	650.00K
Total Growth	-77.06%	1612.94%	7700.00%	-56.15%	-54.42%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United States	87.37M	380.79M	22.23M	285.00K	650.00K
United States Growth	-77.06%	1612.94%	7700.00%	-56.15%	-54.42%
Total	87.37M	380.79M	22.23M	285.00K	650.00K
Total Growth	-77.06%	1612.94%	7700.00%	-56.15%	-54.42%

Source: S&P Global Market Intelligence.